Snapshot: Adolfo Garcia-Sastre

Adolfo Garcia-Sastre of the Mount Sinai School of Medicine in New York, US, shares his experiences in working with influenza virus

Like Comment

Name: Adolfo Garcia-Sastre

Affiliation: Professor of Microbiology

                  Professor of Medicine, Infectious Diseases

                  Director, Global Health and Emerging Pathogens Institute

                  Director, Center for Research on Influenza Pathogenesis

                  Mount Sinai School of Medicine

                  New York, US





Could you tell me a bit about what your research entails?

Research in my lab focuses on a wide variety of viral pathogens, as well as host-pathogen interactions,  vaccine and anti-viral drug development. A major focus of the lab is on influenza virus research. Influenza viruses are globally important human pathogens infecting up to 500 million people annually. With the recent emergence of highly pathogenic avian influenza (HPAI) strains, there is a pressing need to understand the pathogenesis of influenza A and develop vaccines and therapies. Our laboratory investigates the molecular biology of influenza viruses and several other negative strand RNA viruses. We developed reverse genetics techniques that allow for the generation of recombinant influenza viruses from plasmid DNA, which has led to major breakthroughs in revealing the molecular basis of influenza virus pathogenicity.

I was the principal investigator of a program project grant funded by NIAID from 2004 to 2011 entitled “Molecular and Biological Characterization of Pandemic Flu”, the main goal of which was to understand the signatures of virulence of pandemic human influenza viruses using genetics, structural, molecular biology, pathology, animal models and genomics tools. As part of this PPG and in collaboration with Chris Basler, Peter Palese and Terry Tumpey, we determined the signatures of virulence of the 1918 pandemic virus after its resurrection under biocontainment at the CDC, based on the viral genome sequence obtained by Jeff Taubenberger from tissue lung specimens of human patients who died 100 years ago from the 1918 pandemic.


How did you become interested in influenza research?

I did my PhD in Spain at the University of Salamanca during the end of the 1980s, on the enzymatic properties of several viral neuraminidases, including the neuraminidase of influenza A virus. This sparked a keen interest in influenza viruses, and I decided to continue my studies through a postdoctoral fellowship under the direction of Peter Palese at Mount Sinai School of Medicine in New York in 1991. Dr. Palese’s group has always been at the forefront of influenza research and in 1990 his laboratory developed the first technique that made possible the genetic manipulation of the influenza virus and the use of modern bimolecular biology techniques to study its biology. Since then I have being working on influenza.


In what ways has the 1918 pandemic most influenced your research, and the wider virology and public health field?

The influenza virus that caused the 1918 pandemic remains an example of how devastating influenza pandemics can be. This makes it imperative to increase our understanding of how we can mitigate influenza in humans, in order to prevent future influenza pandemics.


What do you see as the biggest accomplishments/breakthroughs in the field since the 1918 pandemic? Are there any papers that you feel are must reads for those that aren’t familiar with the field (and briefly, why)?

I think there have been two major breakthroughs.

1. The first isolation and culture of human influenza virus, that allowed its study under experimental conditions and the development of the first influenza vaccines:

W. Smith, C.H. Andrewes & P. P. Laidlaw. A virus obtained from influenza patients. Lancet, 222:66-68 (1933)   

2. The development of techniques to rescue influenza viruses from plasmid DNA, which allowed the molecular study of the virus and of its tropism and disease determinants, as well as the generation of modern improved influenza virus vaccines. This was achieved in 1999 independently by two different groups of investigators (I had the privilege of being part of one of the groups):

G. Neumann, T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom & Y. Kawaoka. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. (USA), 96:9345–9350 (1999)

E. Fodor, L. Devenish, O. G. Engelhardt, P. Palese, G. G. Brownlee & Adolfo García-Sastre. Rescue of influenza A virus from recombinant DNA. J. Virol., 73: 9679–9682 (1999)


What do you see as the main challenges for research in your part of the field in the coming years?

We have known for many years that the current influenza virus vaccines are not optimal, necessitate of annual reformulation and use due to antigenic changes in the circulating influenza viruses, and that there are limitations that prevent their timely use to mitigate the effects of pandemic influenza during the first wave of infections.  While newly developed experimental vaccination strategies give hope that better and broad protective universal influenza vaccines could be made, it remains to be seen whether such strategies are safe and immunogenic in humans, and these studies will be lengthy and expensive.

Nonia Pariente

Chief Editor, Nature Microbiology

I come from a mid-sized city on the northwestern coast of Spain. My interest in science initially took me to Madrid, where I finished university and received a PhD in molecular biology. In Madrid, I studied RNA virus evolution and new antiviral strategies with Esteban Domingo. I then moved to UCLA, where I focused on developing lentiviral vectors for gene therapy in Irvin Chen’s laboratory. In 2007, I made the plunge from bench to desk and joined the EMBO Reports editorial team as Reviews Editor, becoming Scientific Editor two years later and Senior Editor in 2012. At EMBO Reports, I was responsible for microbiology and immunology, among other areas, and spent many years expanding my understanding and love for all things microbial. In the summer of 2015, I joined the Nature Microbiology editorial launch team, handling all things related to virology and mycology (and for a brief while parasitology) and -after a couple of stints covering microbiology at Nature- I became the Chief Editor of Nature Microbiology in 2019. I look forward to interacting with the community and providing a venue to publish the most important advances in the field.